New Data for Bioerodible DURAVYU in Wet AMD

Tarek S. Hassan provides perspective on the Phase 3 LUGANO topline results and the path forward for DURAVYU in wet age-related macular degeneration (AMD)

September 17, 2026
5 min

The Ophthalmologist

Overview

The Phase 3 LUGANO trial of DURAVYU (EYP-1901) did not meet its primary endpoint for mean change in best-corrected visual acuity (BCVA) compared to aflibercept.

Background

Wet age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, necessitating effective treatment options. Anti-VEGF therapies are standard, but high treatment burdens can lead to nonadherence. DURAVYU, a bioerodible intravitreal insert, aims to provide sustained release of vorolanib.

Data Highlights

No numerical data available in the source material.

Key Findings

The primary endpoint of mean change in BCVA was not met in the full dataset of the LUGANO trial.
Nine patients in the DURAVYU group experienced ≥15-letter vision loss from causes unrelated to neovascular AMD.
76% of DURAVYU-treated patients remained supplement-free at Week 32, reducing treatment burden by 42% compared to aflibercept.
Anatomic disease control was strong, with only a 4 µm difference in CST compared to aflibercept.
No significant safety signals were identified that could explain the vision loss imbalance.

Clinical Implications

The findings from the LUGANO trial suggest that while DURAVYU may not meet primary efficacy endpoints, it shows promise in secondary outcomes related to treatment burden and anatomic control. Clinicians should consider these factors when evaluating treatment options for wet AMD.

Conclusion

DURAVYU presents a potential alternative for managing wet AMD, with ongoing studies expected to provide further insights into its efficacy and safety.